UNSPSC 51273807: Benzalkonium chloride/benzocaine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.

UNSPSC 51273807 Benzalkonium chloride/benzocaine is a Commodity code whose recent state and local procurement activity shows little alignment with the nominal chemical compound in its name. Recent opportunities tagged to this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which are benzalkonium chloride or benzocaine formulations. The mismatch suggests the code's application to state and local health and human services purchasing may be miscategorized or used as a proxy classification where more specific pharmaceutical codes are unavailable in the issuing jurisdiction's taxonomy.

Issuing bodies soliciting under this code include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the Texas Health and Human Services Commission issued a Request for Information (HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products, with responses due March 26, 2026, and contract effectiveness July 1, 2026. Activity is concentrated in Florida, Texas, and Minnesota, with Minnesota's cooperative vehicle serving multiple states including Oregon. Given the divergence between the code's chemical specificity and the broader pharmaceutical and health-services procurement being classified under it, the code shows limited relevance to firms supplying the actual named compounds.